Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality

H. Harada,Mitsumasa Watanabe,Kenshi Suzuki,S. Yanagita,Takahiro Suzuki,Y. Yoshida,A. Kimura,M. Tsudo,A. Matsuda,K. Tohyama,M. Taniwaki,K. Takeshita,M. Takatoku,K. Ozawa
DOI: https://doi.org/10.1007/s12185-009-0400-8
2009-08-25
International Journal of Hematology
Abstract:
What problem does this paper attempt to address?